Xcout Intel
Oblenio Bio
Oblenio Bio is a biotechnology research company headquartered in Lexington, Massachusetts, focused on transforming the treatment of refractory autoimmune diseases by delivering a broad immune system reset.
Subscribe to see Oblenio Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Oblenio Bio at a glance
Oblenio Bio is a biotechnology company headquartered in United States. It has raised at least $62M across the 2 funding rounds on record, 1 of them with a disclosed amount. Its most recent funding round, Series A, raised $62M in June 2026. Xcout tracks 8 named people at Oblenio Bio, including Samantha Truex (Chief Executive Officer).
Oblenio Bio leadership
- Samantha TruexChief Executive Officer
- Tapan ManiarChief Medical Officer
- Rohan LathiaSVP Corporate Development and Strategy
- Iris CheongVice President, Controller
- Sara BurkeVice President, Program Lead
- Tara BarreiraVice President, Technical Operations
2 more named people on record for Oblenio Bio, with roles, board committees and tenure — see the full roster →
Oblenio Bio funding rounds
At least $62M raised across the 2 rounds on record (1 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $62M | 5 named | |
| — | Undisclosed | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Oblenio Bio competitors
A few of Oblenio Bio's closest competitors — see the full list of competitors and alternatives →
Zag Bio is a biotechnology research company headquartered in Cambridge, Massachusetts. The enterprise focuses on developing innovative therapies for autoimmune diseases by targeting the thymus gland to engage the body's natural T cell central tolerance mechanisms.
Ouro Medicines is a biotechnology company headquartered in South San Francisco, California, developing immune reset therapeutics for chronic immune-mediated diseases.
Abcuro, Inc. is a biotechnology company headquartered in Newton, Massachusetts, focused on developing advanced immunotherapies to treat autoimmune diseases and cancer.
Agenus Inc. is a biotechnology company headquartered in Lexington, Massachusetts, focused on the discovery and development of better immunotherapies and cancer treatments.
Kanyos Bio, Inc. is a biotechnology company located in Cambridge, Massachusetts, created as a subsidiary of Anokion SA to develop clinical candidates for immune tolerance.
AbolerIS Pharma is a pre-clinical stage biotech company founded in Nantes, France, specializing in the development of innovative immunomodulators and advanced biopharmaceuticals for autoimmune conditions.
Get Oblenio Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Oblenio Bio in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access